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Abstract 
Background: Acute kidney injury (AKI) is a frequent form of organ injury in cardiogenic shock. However, data on AKI 
markers such as plasma proenkephalin (P‑PENK) and neutrophil gelatinase‑associated lipocalin (P‑NGAL) in cardio‑
genic shock populations are lacking. The objective of this study was to assess the ability of P‑PENK and P‑NGAL to 
predict acute kidney injury and mortality in cardiogenic shock.
Results: P‑PENK and P‑NGAL were measured at different time points between baseline and 48 h in 154 patients 
from the prospective CardShock study. The outcomes assessed were AKI defined by an increase in creatinine within 
48 h and all‑cause 90‑day mortality. Mean age was 66 years and 26% were women. Baseline levels of P‑PENK and 
P‑NGAL (median [interquartile range]) were 99 (71–150) pmol/mL and 138 (84–214) ng/mL. P‑PENK > 84.8 pmol/mL 
and P‑NGAL > 104 ng/mL at baseline were identified as optimal cut‑offs for AKI prediction and independently associ‑
ated with AKI (adjusted HRs 2.2 [95% CI 1.1–4.4, p = 0.03] and 2.8 [95% CI 1.2–6.5, p = 0.01], respectively). P‑PENK and 
P‑NGAL levels at baseline were also associated with 90‑day mortality. For patients with oliguria < 0.5 mL/kg/h for > 6 h 
before study enrollment, 90‑day mortality differed significantly between patients with low and high P‑PENK/P‑NGAL 
at baseline (5% vs. 68%, p < 0.001). However, the biomarkers provided best discrimination for mortality when meas‑
ured at 24 h. Identified cut‑offs of P‑PENK24h > 105.7 pmol/L and P‑NGAL24h > 151 ng/mL had unadjusted hazard ratios 
of 5.6 (95% CI 3.1–10.7, p < 0.001) and 5.2 (95% CI 2.8–9.8, p < 0.001) for 90‑day mortality. The association remained 
significant despite adjustments with AKI and two risk scores for mortality in cardiogenic shock.
Conclusions: High levels of P‑PENK and P‑NGAL at baseline were independently associated with AKI in cardiogenic 
shock patients. Furthermore, oliguria before study inclusion was associated with worse outcomes only if combined 
with high baseline levels of P‑PENK or P‑NGAL. High levels of both P‑PENK and P‑NGAL at 24 h were found to be 
strong and independent predictors of 90‑day mortality.
Trial registration: NCT01374867 at www.clini caltr ials.gov, registered 16 Jun 2011—retrospectively registered
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Background
Cardiogenic shock is a severe state of hypoperfusion, 
caused by low cardiac output, resulting in end-organ 
hypoperfusion and congestion [1]. Despite recent 
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advances in treatment, cardiogenic shock still carries a 
high mortality rate of 40–60% [2]. Acute kidney injury 
(AKI) is a frequent form of organ injury in cardiogenic 
shock, affecting ~ 30% of patients surviving the initial 
stage [3]. Traditionally, serum creatinine and urine out-
put are used to define AKI [4], but these markers are 
limited by delayed changes following kidney injury and 
have low sensitivity and specificity [5]. Prediction of AKI 
with biomarkers such as neutrophil gelatinase-associated 
lipocalin (NGAL) and proenkephalin (PENK) have been 
studied in critically ill patients [6, 7], but similar studies 
among cardiogenic shock patients are lacking.
PENK is a small endogenous opioid peptide, which is 
cleaved from the common endogenous opioid precursor, 
and thus can be used as a surrogate marker for the activ-
ity of the endogenous opioid system [8]. The opioid sys-
tem has been shown to have depressive effects on cardiac 
and renal function, and has been implicated in the prog-
nosis of myocardial infarction [9]. PENK and the opioid 
system have also been shown to be associated with worse 
outcomes both in acute [10, 11] and chronic heart fail-
ure [11]. PENK has been shown to have a strong nega-
tive correlation with eGFR measured by iohexol and is 
therefore a kidney biomarker of glomerular function [12]. 
PENK was selected as biomarker for this study as it has 
also been shown to predict AKI in patients with severe 
sepsis or shock [13].
NGAL is a member of the lipocalin protein family 
which is expressed in the kidney tubular structures, as 
well as other tissues [14]. NGAL is rapidly released in 
response to tubular damage [15, 16], and is one of the 
most extensively studied biomarkers used for AKI pre-
diction [17].
Our aim was to assess the predictive value of P-PENK 
and P-NGAL for AKI within 48  h after admission and 
90-day all-cause mortality in patients with cardiogenic 
shock.
Methods
Study design
The CardShock study (NCT01374867 at www.clini caltr 
ials.gov) was a European prospective, observational, mul-
ticenter and multinational study on cardiogenic shock. 
Patients were recruited between October 2010 and 
December 2012 from emergency departments, cardiac 
and intensive care units, as well as catheterization labora-
tories from nine tertiary hospitals in eight countries. For 
a detailed design and description of the study population 
please see Harjola et al. [18].
Participants
Consecutive patients older than 18  years were enrolled 
in the study within 6 h from identification of cardiogenic 
shock. Written informed consent was obtained from the 
patient or next of kin if the patient was unable to give 
consent. To be included in the study, the patients needed 
to have (1) an acute cardiac cause for the shock, (2) sys-
tolic blood pressure < 90  mmHg (after adequate fluid 
challenge) for 30 min or a need for vasopressor therapy 
to maintain systolic blood pressure > 90  mmHg, and (3) 
signs of hypoperfusion (one or several of the following: 
altered mental status, cold periphery, oliguria < 0.5  mL/
kg/h for the previous 6  h, or blood lactate > 2  mmol/L). 
Exclusion criteria were shock caused by ongoing hemo-
dynamically significant arrhythmia or shock after car-
diac or non-cardiac surgery. Baseline characteristics and 
previous medical history were recorded. Biochemical 
and clinical findings as well as hemodynamic param-
eters were documented at detection of shock and at pre-
specified time points up to 48 h after inclusion. Patients 
were treated according to local practice and treatment 
and procedures were registered. Local investigators were 
responsible for determining the etiology of cardiogenic 
shock. Acute coronary syndrome etiology was defined 
as shock caused by myocardial infarction (with or with-
out ST-elevation). Echocardiography was performed per 
protocol at study inclusion. Coronary angiography was 
carried out in 128 patients, of which 95 (74%) were done 
before study inclusion, and 24 (19%) within 12  h after 
study inclusion.
Test methods
Plasma samples were collected at baseline in 178/219 
patients enrolled in the CardShock study. Additionally, 
serial blood samples were collected at 12  h, 24  h, 48  h 
(all ± 3  h) and at discharge from ICU (5–10  days) (see 
Additional file 1: Fig. 1 for a diagram). A baseline sample 
and at least one additional sample within 48 h were avail-
able for 154 patients, which constitute the study popula-
tion in this report. After collection, the blood sample was 
centrifuged, and separated plasma was immediately fro-
zen in aliquots and stored at − 80  °C. PENK concentra-
tions in plasma were determined using the  Sphingotest® 
penKid immunoassay (SphingoTec GmbH, Hennigsdorf, 
Germany). Plasma NGAL concentrations were deter-
mined with a commercially available particle-enhanced 
turbidimetric immunoassay (BioPorto Diagnostics A/S, 
Hellerup, Denmark). Creatinine, C-reactive protein 
(CRP), high-sensitivity troponin T, N-terminal pro-B-
type natriuretic peptide (NT-proBNP), alanine ami-
notransferase, alkaline phosphatase, total bilirubin and 
cystatin C were analyzed from the plasma samples using 
commercially available standard kits (Abbott Laborato-
ries, Abbott Park, IL, USA for cystatin C, Roche Diag-
nostics, Basel, Switzerland for all other tests) at a central 
accredited laboratory (ISLAB, Kuopio, Finland). Arterial 
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blood gas analysis (including arterial pH and lactate), 
hemoglobin and leucocytes were analyzed by local labo-
ratories. Estimated glomerular filtration rate (eGFR) was 
calculated from creatinine values using the Chronic Kid-
ney Disease Epidemiology Collaboration equation [19]. 
AKI was defined and staged according to the Kidney Dis-
ease: Improving Global Outcomes (KDIGO) criteria [4]. 
For AKI staging at baseline, a recently described staging 
which includes biomarker levels was used [5]. Urine out-
put was recorded at 6, 12, 18, and 24 h and used for urine 
output-based definitions of AKI. Main outcomes investi-
gated in this study were AKI defined by an increase cre-
atinine of more than 26,5  μmol/L within 48  h of study 
inclusion  (AKIcrea48h) and all-cause 90-day mortality. 
Assessment of  AKIcrea48h was based on creatinine levels 
from baseline until 48 h, and the highest increase within 
this time was used for staging. AKI staging by urine out-
put was categorized according to the lowest urine out-
put for a time interval within the first 24  h. Subclinical 
AKI was defined as positive biomarker (either P-PENK 
or P-NGAL > cut-off) but no  AKIcrea48h. Vital status of 
the patients during follow-up was determined through 
direct contact with the patient or next of kin, or through 
population and hospital registers. Patients with missing 
plasma samples were left out of the analysis. Two patients 
were lost to follow-up and were left out of the survival 
analyses. The study was approved by local ethics commit-
tees and conducted in accordance with the Declaration 
of Helsinki. Two published risk scores for cardiogenic 
shock, CardShock risk Score [18] and IABP SHOCK 
II score [20] were calculated for every patient to assess 
whether P-PENK or P-NGAL provided additive value in 
risk prediction.
Statistical analysis
Results are presented as number (n) and percentage (%), 
mean and standard deviation (SD), or median and inter-
quartile range (IQR) as appropriate. Group comparisons 
were performed using Fisher’s exact test for categorical 
variables, and Student’s t test or Mann–Whitney U test for 
continuous variables, as appropriate. Associations between 
continuous variables were assessed using Spearman cor-
relations. Youden index was used to select the cut-offs of 
P-PENK and P-NGAL used for AKI and mortality predic-
tion. To determine variables independently associated with 
P-PENK and P-NGAL levels univariable general linear 
models were constructed using log-normalized P-PENK 
and P-NGAL levels as dependent variables. Differences in 
survival between groups were assessed comparing Kaplan–
Meier survival curves using log-rank test. Cox regres-
sion models were used to assess associations of variables 
with AKI and mortality in uni- and multivariable models. 
Forward and backward selection of variables was used in 
multivariable Cox regression models to calculate likelihood 
ratios, using a significance of > 0.10 for elimination and a 
significance of < 0.05 for retention. The additive value of a 
variable in the multivariable Cox regression models was 
assessed using likelihood ratio test for nested models. The 
proportionality of hazards assumption was tested using 
log-minus-log plots. Hazard ratios (HR) for Cox regres-
sion analyses are shown with 95% confidence intervals 
(CIs). Discriminative capability of P-PENK and P-NGAL 
at different time points was assessed using the area under 
receiver-operating characteristics curve (AUC). The statis-
tical significance of changes between different time points 
in P-PENK and P-NGAL levels was assessed using Wil-
coxon signed ranks test. Differences in P-PENK, P-NGAL, 
and creatinine trajectories between different groups were 
assessed using linear mixed modeling. Two-sided p val-
ues < 0.05 were regarded as statistically significant. Data 
were analyzed using the SPSS statistical package, version 23 
(IBM Corp, Armonk, NY, USA). STATA (StataCorp. 2019. 
Stata Statistical Software: Release 16. College Station, TX: 
StataCorp LLC) was used to calculate c-statistics for the 
different Cox regression models.
Results
Patient characteristics
Baseline characteristics of patients (n = 154) stratified by 
P-PENK and P-NGAL quartiles at baseline are presented 
in Table 1. The mean age of all patients in the cohort was 
66  years and 26% of the patients were women. The main 
cause of cardiogenic shock was acute coronary syndrome, 
which accounted for 81% of the cases. The overall 90-day 
mortality was 38%. AKI was observed in 47/154 (31%) 
patients within 48  h of baseline. Most patients (n = 29) 
had AKI already within 12 h from baseline. Median base-
line P-PENK (n = 152) was 105 (IQR 71–167) pmol/mL, 
and median baseline P-NGAL (n = 146) was 138  ng/mL 
(IQR 84–214). Patients with P-PENK > median and patients 
with P-NGAL > median levels had lower eGFR and hemo-
globin at baseline, and had higher levels of creatinine, 
NT-proBNP, alkaline phosphatase and lactate. Oliguria 
prior to enrollment was more frequent in patients with 
biomarker levels > median and they had higher CardShock 
and IABP II Shock risk score points. Patients with PENK/
NGAL > median had a higher incidence of AKI within 48 h 
and their mortality was higher. STARD flow diagrams of 
study participants are provided as Additional file 1: Fig. 2.
Time‑related changes in P‑PENK and P‑NGAL levels 
in patients with/without  AKIcrea48h and survivors/
nonsurvivors
Figure 1 shows the trajectories of P-PENK, P-NGAL and 
creatinine between baseline and 48  h in patients with 
and without  AKIcrea48h and Fig.  2 shows P-PENK and 
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P-NGAL trajectories in survivors and nonsurvivors. In 
nonsurvivors, the increase from baseline to 24 h was sta-
tistically significant for P-NGAL (p = 0.003), but not for 
P-PENK (p = 0.58). There were statistically significant 
differences in both P-PENK and P-NGAL levels with 
respect to time and group, and an interaction between 
the groups with time was observed.
Association of baseline P‑PENK and P‑NGAL levels with AKI, 
renal outcomes, and interventions
AUCs were calculated at each time point for  AKIcrea48h 
and 90-day all-cause mortality to assess the discrimina-
tory capabilities of both biomarkers (Additional file  1: 
Table  1). At baseline, the predictive value of P-PENK0h 
and P-NGAL0h for  AKIcrea48h was only moderate (AUCs 
0.621 and 0.664, respectively) (Additional file 1: Table 1). 
Compared to baseline measurements, biomarker values 
at later time points had better performance in prediction 
of  AKIcrea48h. However, since most AKI cases occurred 
within 12 h from baseline, P-PENK and P-NGAL meas-
urements in time points later than baseline were not 
considered for AKI prediction. The optimal biomarker 
cut-off value at baseline for predicting  AKIcrea48h was 
found to be 84.8 pmol/mL for P-PENK0h and 104 ng/mL 
for P-NGAL0h. In univariable Cox regression analysis, 
both P-PENK0h > 84.8 pmol/mL and P-NGAL0h > 104 ng/
mL were associated with the development of AKI 
(Table  2). Multivariable regression modeling identi-
fied high P-PENK0h (adj HR 2.2 [95% CI 1.1–4.4] and 
P-NGAL0h (adj HR 2.8 [95% CI 1.2–6.5]) as being inde-
pendently associated with  AKIcrea48h (Table  2). Table  3 
shows renal outcomes and differences in interventions 
using these P-PENK0h and P-NGAL0h cut-offs. There 
were 51 (34%) patients, who fulfilled the criteria for AKI 
stage 1S. In patients with oliguria at baseline but with-
out high PENK or NGAL (stage 1A) only 2/16 (13%) of 
patients developed AKIcrea48h, compared with 13/51 
(26%) of patients in stage 1S and 33/63 (48%) in stage 1B 
(p = 0.001). Only 1/21 (5%) of patients in stage 0 devel-
oped AKIcrea48h. High P-PENK0h was associated with 
very early AKI (< 24  h), whereas high P-NGAL0h was 
also associated with AKI detected at 24–48  h (p < 0.05 
for comparisons between subsets). Both high P-PENK0h 
and high P-NGAL0h were associated with AKI as defined 
by low urine output according to the KDIGO criteria, 
whereas only high P-NGAL0h was associated with AKI 
as defined by an increase in Cystatin C. High P-NGAL0h 
was also associated with the use of renal replacement 
therapy, whereas high P-PENK0h was not. Figure 3 shows 
Kaplan–Meier curves for the development of  AKIcrea48h 
for high P-PENK and high P-NGAL groups. Cross tabu-
lation of high P-PENK and P-NGAL levels with respect 
to  AKIcrea48h can be seen in Additional file 1: Table 3.
Association of baseline levels of P‑PENK and P‑NGAL 
with 90‑day mortality
The relationships between AKI, 90-day mortality and 
high P-PENK0h and/or P-NGAL0h are depicted as a 
Venn diagram in Fig.  4. 90-day mortality differed sig-
nificantly between AKI stages at admission (7% for 
stage 0, 19% for stage 1S, 5% for stage 1A and 68% 
for stage 1B, p < 0.001). Both P-PENK0h > 84.8  pmol/
mL and P-NGAL0h > 104  ng/mL were associated with 
higher 90-day mortality (Table  3). Figure  5 shows the 
survival curves for patients with and without  AKIcrea48h 
separated by baseline P-PENK (panel A) and baseline 
P-NGAL (panel B) higher (subclinical AKI) or lower 
than the optimal cut-off for AKI prediction (84.8 pmol/
mL for P-PENK0h and 104 ng/mL for P-NGAL0h). Using 
the cut-offs predictive of AKI, P-NGAL0h > 104  ng/mL 
was able to further stratify patients with and without 
 AKIcrea48h further into high or low mortality risk groups 
(Fig. 5).
Utility of P‑PENK and P‑NGAL at later time points 
for mortality risk stratification in cardiogenic shock
Although high levels of both P-PENK and P-NGAL were 
associated with higher mortality at all time points exam-
ined, the AUC for mortality was highest for both bio-
markers measured at 24 h (Additional file 1: Table 2). The 
AUCs for 90-day mortality for CardShock risk score and 
IABP SHOCK II risk score at 24 h were 0.778 and 0.707.
The optimal cut-off for mortality was 105.7  pmol/
mL for P-PENK24h, and 151  ng/mL for P-NGAL24h. 
Survival curves using these cut-offs showed that for 
patients with P-PENK24h > 105.7  pmol/mL 90-day mor-
tality was 68.2% compared with 17.4% for patients with 
P-PENK24h < 105.7  pmol/mL. Similarly, 90-day mortality 
for patients with P-NGAL24h > 151 ng/mL was 63.5% com-
pared with 17.7% for patients with P-NGAL24h < 151 ng/
mL (p < 0.001 for all, Additional file 1: Fig. 2).
In univariable Cox regression, both 
P-PENK24h > 105.7  pmol/mL and P-NGAL24h > 151  ng/
mL were strongly associated with mortality (Table  4). 
In multivariable analysis, the associations of both 
P-PENK24h > 105.7  pmol/mL and P-NGAL24h > 151  ng/
mL with higher mortality were found to be independent 
of both CardShock risk score and IABP II Shock score. 
Further adjustment of the multivariable models with 
 AKIcrea48h did not change the independent association 
of P-PENK24h with 90-day all-cause mortality, whereas 
P-NGAL24h was no longer significantly associated with 
90-day mortality after adjusting for both CardShock risk 
score and  AKIcrea48h. Cross tabulation of P-PENK24h and 
P-NGAL24h with respect to 90-day mortality can be seen 
in Additional file 1: Table 3.
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Determinants of P‑PENK and P‑NGAL in cardiogenic shock
Results from a Spearman correlation analysis with base-
line variables and levels of P-PENK and P-NGAL are 
shown in Additional file  1: Table  2. Markers of renal 
function had moderate to strong correlations with both 
P-PENK and P-NGAL at baseline. P-PENK and P-NGAL 
were also intercorrelated. General linear model analysis 
showed that the biomarkers had strongest associations 
with eGFR (F-statistic 82.8 for P-PENK and 84.9 for 
P-NGAL; p < 0.001 for both) and log-normalized lactate 
levels at baseline (F-statistic 5.0; p = 0.03 for P-PENK 
and 16.4; p < 0.001 for P-NGAL). In addition, body mass 
index (F-statistic 6.0, p = 0.02) and alkaline phosphatase 
(F-statistic 5.0, p = 0.03 were independent associates 
of P-NGAL levels. eGFR alone accounted for 36% of 
the observed variance of P-PENK and 39% of P-NGAL 
variance.
Discussion
This multicenter cohort study is the first to investigate 
P-PENK and P-NGAL in cardiogenic shock of various 
etiologies. We describe the early kinetics of P-PENK 
Fig. 1 Biomarker medians at different time points separated by occurrence of AKI within 48 h. a P‑PENK. b P‑NGAL. c Creatinine. Error bars = 95% 
confidence interval
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and P-NGAL and their associations with markers of 
kidney function, AKI and outcomes. The main findings 
can be summarized as follows. Firstly, both P-PENK and 
P-NGAL at baseline correlated with markers of kidney 
function. Secondly, high baseline levels of both studied 
markers were associated with the development of AKI 
within 48 h. Thirdly, subclinical AKI at baseline was asso-
ciated with increased mortality both in patients with 
oliguria before study enrollment as well as in patients 
without  AKIcrea48h. Finally, although high levels of 
P-PENK and P-NGAL were associated with worse out-
comes at all studied time points, P-PENK and P-NGAL 
levels at 24 h had the best discriminatory capabilities on 
survival. They were also associated with mortality inde-
pendently of the development of AKI and two separate 
risk scores designed to assess the prognosis of patients in 
cardiogenic shock.
P‑PENK and P‑NGAL as predictors of AKI
Elevated levels of P-PENK and P-NGAL were both 
associated with the development of  AKIcrea48h and had 
comparable discriminatory properties in AUC analysis. 
Interestingly, we found that  AKIcrea48h occurred almost 
solely if oliguria (< 0.5  mL/kg/h for > 6  h) before study 
inclusion was combined with subclinical AKI at baseline. 
P-NGAL has been shown to predict AKI after cardiac 
surgery [21], in critically ill children [22] and adults [23] 
with suggested cut-offs ranging from 100 to 270 nmol/mL 
[24]. In a recent meta-analysis comparing plasma/serum 
NGAL, urine NGAL and serum cystatin C, plasma/
Fig. 2 P‑PENK and P‑NGAL median levels at different time points separated by 90‑day mortality. a P‑PENK. b P‑NGAL. Error bars = 95% confidence 
interval
Table 2 Multivariable Cox regression models with P-PENK and P-NGAL at baseline for prediction of  AKIcrea within 48 h
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, NGAL neutrophil gelatinase-associated lipocalin, PENK proenkephalin
* 2 log-likelihood test for additive value of P-PENK/P-NGAL in the model
Hazard ratio 95% CI p value p value 
for addition*
c‑statistic 
with PENK/NGAL
c‑statistic 
without PENK/
NGAL
Model 1
 P‑PENK > 84.8 pmol/mL at baseline 2.2 1.1–4.4 0.03 0.02 0.689 0.677
 Prior use of diuretics 2.4 1.2–4.9 0.01
  Arterial pH 0.7 0.6–0.9 0.01
 Prior use of ACEI or ARB 0.4 0.2–0.8 0.01
Model 2
 P‑NGAL > 104 ng/mL at baseline 2.8 1.2–6.5 0.01 0.007 0.684 0.634
 Arterial pH 0.9 0.7–1.1 0.14
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Table 3 Differences in renal outcomes, interventions, and mortality by P-PENK and P-NGAL cut-offs at baseline
Results shown as n (%) for categorical and mean (SD) or median (IQR) for continuous variables
AKI acute kidney injury, CysC cystatin C, ECMO extracorporeal membrane oxygenation, eGFR estimated glomerular filtration rate, IABP intra-aortic balloon pump, 
ICU intensive care unit, IQR interquartile range, LVAD left ventricular assist device, NGAL neutrophil gelatinase-associated lipocalin, PENK proenkephalin, RRT renal 
replacement therapy, SD standard deviation
a AKI staging on admission based on urine output and biomarkers, as data on creatinine prior to baseline were unavailable
b KDIGO definition of increase in serum creatinine to 1.5 times baseline or more
All PENK 
at 0 h < 84.8 pmol/
mL
PENK 
at 0 h > 84.8 pmol/
mL
p value P‑NGAL 
at 0 h < 104 ng/
mL
P‑NGAL 
at 0 h > 104 ng/
mL
p value
(N = 154) (N = 61) (N = 91) (N = 49) (N = 97)
AKI staging at  baselinea
 Stage 0 21 (14%) 21 (14%) 0 (0%) < 0.001 17 (12%) 0 (0%) < 0.001
 Stage 1S 51 (34%) 12 (8%) 38 (26%) 13 (9%) 36 (25%)
 Stage 1A 16 (11%) 16 (11%) 0 (0%) 15 (10%) 0 (0%)
 Stage 1B 63 (42%) 11 (7%) 51 (34%) 3 (2%) 60 (42%)
Detection of AKI by increase in creati‑
nine after baseline
 AKI by 12 h 29 (19%) 5 (8%) 23 (25%) 0.05 5 (10%) 24 (25%) 0.006
 AKI 12–24 h 6 (4%) 2 (3%) 4 (4%) 1 (2%) 5 (5%)
 AKI 24–36 h 10 (7%) 4 (7%) 6 (7%) 0 (0%) 9 (9%)
 AKI 36–48 h 2 (1%) 0 (0%) 2 (2%) 1 (2%) 1(1%)
 AKI 48 h‑discharge from ICU 
(5–10 days)b
6 (4%) 2 (3%) 4 (4%) 0.73 3 (6%) 3 (3%) 0.38
 AKI CysC 49 (33%) 17 (29%) 32 (36%) 0.32 9 (18%) 40 (42%) 0.005
 AKI severity by urine output after 
baseline
 No 75 (50%) 37 (61%) 38 (42%) 0.04 31 (63%) 42 (44%) 0.02
 Stage 1 33 (22%) 13 (21%) 20 (22%) 11 (22%) 19 (20%)
 Stage 2 or 3 43 (29%) 11 (18%) 32 (36%) 7 (14%) 35 (37%)
AKI severity within 48 h of baseline by creatinine 
(RRT excluded from staging)
0.008 0.005
 No AKI 106 (70%) 50 (82%) 56 (61%) 42 (86%) 58 (60%)
 Stage 1 27 (18%) 9 (15%) 18 (20%) 5 (10%) 22 (23%)
 Stage 2 or 3 (RRT excluded) 19 (12%) 2 (3%) 17 (19%) 2 (4%) 17 (17%)
 History of renal insufficiency 17 (11%) 1 (2%) 16 (18%) 0.003 0 (0%) 17 (18%) 0.002
Interventions
 Renal replacement therapy 22 (14%) 7 (12%) 15 (17%) 0.49 3 (6%) 19 (20%) 0.048
 Ultrafiltration 11 (8%) 2(4%) 9 (11%) 0.20 2 (5%) 9 (11%) 0.33
 Hemodialysis 7 (5%) 0 (0%) 7 (9%) 0.04 0 (0%) 7 (8%) 0.10
 Use of vasopressors 126 (83%) 50 (82%) 76 (84%) 0.83 41 (84%) 81 (84%) 0.99
 Use of adrenaline 21 (14%) 7 (12%) 14 (15%) 0.63 2 (4%) 18 (19%) 0.02
 Use of noradrenaline 114 (75%) 44 (72%) 70 (77%) 0.57 39 (80%) 73 (75%) 0.68
 Use of dobutamine 25 (16%) 11 (18%) 14 (15%) 0.82 5 (10%) 18 (19%) 0.23
 History of renal insufficiency 17 (11%) 1 (2%) 16 (18%) 0.003 0 (0%) 17 (18%) 0.002
 Coronary angiography 128 (83%) 55 (90%) 71 (78%) 0.08 45 (92%) 75 (77%) 0.04
 Amount of contrast used; mL (SD) 189 (104) 192 (106) 186 (105) 0.72 183 (113) 197 (102) 0.29
 Amount of contrast used per eGFR; 
mL/eGFR (SD)
3.4 (2.4) 2.5 (1.6) 4.1 (3.0) 0.005 2.3 (1.8) 4.2 (3.6) < 0.001
 IABP use 86 (57%) 39 (64%) 47 (52%) 0.18 27 (55%) 56 (58%) 0.86
 Intubated 93 (62%) 36 (60%) 57 (63%) 0.73 28 (57%) 61 (64%) 0.47
 LVAD or ECMO 6 (4%) 2 (3%) 4 (4%) 0.99 1 (2%) 4 (4%) 0.66
90‑day mortality 58 (38%) 15 (25%) 42 (47%) 0.006 9 (18%) 49 (52%) < 0.001
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serum NGAL was found to be the earliest marker pre-
dicting contrast-induced nephropathy [25]. Of the two 
markers investigated in the present study, only P-NGAL 
was associated with renal replacement therapy and AKI 
assessed by changes in cystatin C plasma concentrations, 
suggesting P-NGAL may be a more robust indicator of 
AKI and other renal outcomes. For most patients who 
developed AKI, it occurred very early, which makes it 
most likely related to the acute state of cardiogenic shock 
and not secondary to other events in-hospital. Thus, 
based on our findings, the ability to predict the occur-
rence and severity of AKI using biomarkers measured at 
presentation opens a narrow window of opportunity for 
targeted interventions.
Biomarker trajectories in AKI and nonsurvivors
Overall, levels of P-PENK and P-NGAL decreased from 
0 to 48  h. In nonsurvivors and patients who developed 
AKI within 48 h the levels were higher at all time points 
for both P-PENK and P-NGAL compared to survivors 
and patients without AKI. While the absolute levels dif-
fered, the trajectories of P-PENK over time were similar 
in survivors and nonsurvivors. In contrast, for P-NGAL, 
the levels were increasing up to 48 h in nonsurvivors, but 
were stable or declined in survivors. These findings most 
likely represent differences in the production and kinet-
ics of the two biomarkers. In a mouse renal ischemia–
reperfusion injury model, P-NGAL expression has been 
shown to be upregulated in the proximal kidney tubu-
lar cells early in response to renal ischemia with a peak 
Fig. 3 Kaplan–Meier curves for occurrence of acute kidney injury by P‑PENK and P‑NGAL levels at baseline. a Lines separated by 
P‑PENK > 84.8 pmol/mL at baseline. b Lines separated by P‑NGAL > 104 ng/mL at baseline
Fig. 4 Venn diagram of P‑PENK, P‑NGAL at baseline, acute kidney 
injury and 90‑day mortality. PENK high = P‑PENK < 84.8 pmol/mL 
at baseline. P‑NGAL high = P‑NGAL > 104 ng/mL at baseline. For 
illustrative purposes. Areas not proportional, unable to show all 
overlaps
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at 12  h post-ischemia [26], which could explain the ini-
tial increase observed for P-NGAL in nonsurvivors and 
patients who developed AKI and also had higher levels 
of lactate. P-PENK, on the other hand, is a marker of 
the endogenous opioid system activity, which could be 
higher in those with more severe clinical presentation, 
but be more stable over time. P-PENK could also cause 
a deterioration of renal function through cardiodepres-
sion [27], with high initial levels causing a more marked 
decline in kidney function. These pathophysiological 
Fig. 5 Kaplan–Meier survival curves for patients with and without AKI separated by P‑PENK and P‑NGAL levels. a P‑PENK higher or lower than 
84.8 pmol/mL at baseline. b P‑NGAL higher or lower than 104 ng/mL at baseline. §p = 0.07, *p < 0.05, **p < 0.001. AKI acute kidney injury
Table 4 Hazard ratios for  multivariable models of  90-day mortality for  P-PENK24h > 105.7  pmol/mL 
and P-NGAL24h > 151 ng/mL
AKIcrea48h acute kidney injury by creatine increase within 48 h, CI confidence interval, NGAL neutrophil gelatinase-associated lipocalin, PENK proenkephalin
* 2 log-likelihood test for additive value of P-PENK/P-NGAL in the model
Hazard ratio 95% CI p value* c‑statistic c‑statistic 
without PENK/
NGAL
P‑PENK24h > 105.7 pmol/mL at 24 h
Univariable 5.8 3.1–10.7 < 0.001 0.705
Adjusted model 1 (CardShock risk score) 4.5 2.3–8.7 < 0.001 0.778 0.726
Adjusted model 2 (IABP II SHOCK score) 4.2 2.0–9.0 < 0.001 0.750 0.702
Adjusted model 3 (AKIcrea48h) 3.5 1.7–6.9 < 0.001 0.750 0.671
Adjusted model 4 (CardShock risk score + AKIcrea48h) 2.7 1.3–5.6 0.01 0.800 0.781
Adjusted model 5 (IABP II SHOCK score + AKIcrea48h) 2.7 1.2–5.9 0.01 0.773 0.749
P‑NGAL24h > 151 ng/mL at 24 h
Univariable 5.2 2.8–9.8 < 0.001 0.632
Adjusted model 1 (CardShock risk score) 3.4 1.7–6.8 0.001 0.733 0.726
Adjusted model 2 (IABP II SHOCK score) 4.2 2.0–8.9 < 0.001 0.724 0.702
Adjusted model 3 (AKIcrea48h) 3.2 1.6–6.5 0.001 0.716 0.671
Adjusted model 4 (CardShock risk score + AKIcrea48h) 2.0 0.9–4.2 0.07 0.781 0.781
Adjusted model 5 (IABP II SHOCK score + AKIcrea48h) 2.5 1.1–5.9 0.03 0.755 0.749
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mechanisms may be seen to be in concordance with the 
results of our study that patients with high levels of either 
P-PENK or P-NGAL were at significantly higher risk for 
mortality and for developing AKI within 48 h.
Association of P‑PENK and P‑NGAL with mortality
Both P-PENK and P-NGAL showed good discrimina-
tory capabilities for 90-day mortality at all time points 
up to 48  h, with the highest AUCs for both occurring 
at 24  h. High levels of both P-PENK24h and P-NGAL24h 
were associated independently with 90-day mortality 
even after adjusting for the CardShock risk score, IABP 
II SHOCK risk score and AKI. In fact, the AUCs for 
both P-PENK24h and P-NGAL24h were similar to those 
of the risk scores alone. The independent association of 
P-PENK24h and P-NGAL24h with 90-day mortality sug-
gests that they are not just markers for AKI, but may 
also contribute to other unidentified causes of increased 
mortality in the CardShock study population that are not 
included in the relevant risk scores. A recent study in 
critically ill patients suggests that high levels of P-PENK 
in patients without AKI may be a marker of subclinical 
AKI, which was associated with a risk of death close to 
patients with AKI [28]. Similarly in our study, patients 
with subclinical AKI (elevated biomarkers at baseline but 
without  AKIcrea48h) had higher 90-day mortality. Inter-
estingly, P-NGAL was also able to stratify patients with 
 AKIcrea48h into high or low mortality risk groups. It could 
be hypothesized that this might be due to less severe AKI, 
where despite an increase in creatinine the renal injury is 
smaller. Using the recently described AKI staging using 
biomarkers on admission [5], we were also able to show 
that low urine output (< 0.5  mL/kg/h for > 6  h) before 
study inclusion was associated with worse outcomes 
only if combined with high baseline levels of P-PENK or 
P-NGAL.
Elevated P-NGAL may not be specific for acute kidney 
injury, as NGAL is also expressed at low levels in several 
human tissues, including lung, stomach, and colon, as 
well as neutrophils [14]. Serum NGAL levels have been 
shown to increase also with infection, inflammation and 
ischemia [29]. The association of NGAL with inflamma-
tion and ischemia might be a drawback in acute kidney 
injury prediction, but might help explain the high dis-
criminatory capability in 90-day mortality in cardiogenic 
shock, where systemic inflammatory response syndrome 
and end-organ ischemia play an important role. P-PENK 
and P-NGAL could be useful in assessing mortality risk 
of cardiogenic shock patients at later time points for 
which few risk markers have so far been assessed [30]. 
However, although this study offers new insight to pre-
diction of AKI and mortality in cardiogenic shock pop-
ulations, overall data on biomarkers in this area are still 
very limited and more research is warranted. The results 
of our study should be validated in another cohort of car-
diogenic shock patients to confirm our findings.
Study limitations
We did not have plasma samples available for all the Card-
Shock study participants, and also were unable to measure 
P-NGAL for some of the patients in this study. However, this 
is one of the largest cohorts of biomarker studies in patients 
with cardiogenic shock and despite the general challenges 
with serial sampling in acute cardiac care, we consider the 
available samples to be representative of the cohort. One of 
the study limitations is the lack of data on creatinine prior to 
study inclusion. On the other hand, the European Renal Best 
Practice position statement recommends using baseline cre-
atinine values instead of historical values or back-calculated 
value based on an assumed GFR of 75  mL/min/1.73  m2 
[31]. Although adjustments were made for several variables 
in multivariable analyses, there may have been other con-
founding factors we were unable to account for leading to an 
overestimation of the independent association of P-PENK 
and P-NGAL with AKI and mortality.
Conclusions
Our study shows that in cardiogenic shock, P-PENK 
and P-NGAL levels differed between patients who did 
and did not develop AKI within 48 h as well as between 
90-day survivors and nonsurvivors. High levels of both 
P-PENK and P-NGAL at presentation were associated 
with AKI within 48  h. Subclinical AKI at baseline was 
associated with increased mortality both in patients with 
oliguria before study enrollment as well as in patients 
without  AKIcrea48h. Adjusting for AKI and two risk scores 
validated for cardiogenic shock patient populations, high 
levels of P-PENK and P-NGAL at 24 h were still indepen-
dently associated with higher 90-day all-cause mortal-
ity. P-PENK and P-NGAL seem useful biomarkers in the 
early prediction of outcomes in cardiogenic shock popu-
lations, and may have role in the prediction of AKI.
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